nk 611 profile

NK 611: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

ID Source	ID
PubMed CID	9852558
MeSH ID	M0214115

ID Source

PubMed CID

9852558

MeSH ID

M0214115

Synonyms (9)

Synonym
105760-98-3
nk 611
6a2daq3zzw ,
DTXSID90873361
vp 19 hydrochloride
2'-dimethylamino-2'-deoxyetoposide hydrochloride
vp-19 hydrochloride
furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5ah)-one, 9-((2-deoxy-2-(dimethylamino)-4,6-o-(1r)-ethylidene-.beta.-d-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-, hydrochloride (1:1), (5r,5ar,8ar,9s)-
AKOS040753289

Synonym

105760-98-3

nk 611

6a2daq3zzw ,

DTXSID90873361

vp 19 hydrochloride

2'-dimethylamino-2'-deoxyetoposide hydrochloride

vp-19 hydrochloride

furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5ah)-one, 9-((2-deoxy-2-(dimethylamino)-4,6-o-(1r)-ethylidene-.beta.-d-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-, hydrochloride (1:1), (5r,5ar,8ar,9s)-

AKOS040753289

Excerpt	Reference	Relevance
" The overall median pharmacokinetic values were as follows (ranges are given in parentheses): mean residence time (MRT) 16."	( Pharmacokinetics and pharmacodynamics of the new podophyllotoxin derivative NK 611. A study by the AIO groups PHASE-I and APOH. Burk, K; Hanauske, AR; Herbst, K; Hossfeld, DK; Hüttmann, A; Manegold, C; Mross, K; Schilling, T, 1996)	0.29
" The primary objectives of this study were to determine, after both oral and intravenous administration in the same patient, the bioavailability and the pharmacokinetic profile of NK611."	( Clinical and pharmacokinetic study of oral NK611, a new podophyllotoxin derivative. Cavalli, F; D'Incalci, M; De Fusco, M; de Jong, J; Hanauske, A; Kaeser-Fröhlich, A; Pagani, O; Sessa, C; Zucchetti, M, 1996)	0.29
"We have conducted a clinical and pharmacokinetic trial of the novel podophyllotoxin derivative NK611 administered orally for 21 consecutive days."	( Clinical and pharmacokinetic phase I trial of oral dimethylaminoetoposide (NK611) administered for 21 days every 35 days. Hanauske, AR; Kaeser-Fröhlich, A; Rassmann, I; Rastetter, J; Schilling, T; Schrödel, H; Zucchetti, M, 1996)	0.29
" Pharmacokinetic analyses were performed in all patients."	( Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK611 administered as intravenous short infusion. Berdel, WE; Burk, K; Fiebig, HH; Hanauske, AR; Hüttmann, A; Kaeser-Fröhlich, A; Manegold, C; Mross, M; Rassmann, I; Thödtmann, R, )	0.13

Excerpt

Reference

Relevance

" The overall median pharmacokinetic values were as follows (ranges are given in parentheses): mean residence time (MRT) 16."

( Pharmacokinetics and pharmacodynamics of the new podophyllotoxin derivative NK 611. A study by the AIO groups PHASE-I and APOH.
Burk, K; Hanauske, AR; Herbst, K; Hossfeld, DK; Hüttmann, A; Manegold, C; Mross, K; Schilling, T, 1996)

0.29

" The primary objectives of this study were to determine, after both oral and intravenous administration in the same patient, the bioavailability and the pharmacokinetic profile of NK611."

( Clinical and pharmacokinetic study of oral NK611, a new podophyllotoxin derivative.
Cavalli, F; D'Incalci, M; De Fusco, M; de Jong, J; Hanauske, A; Kaeser-Fröhlich, A; Pagani, O; Sessa, C; Zucchetti, M, 1996)

0.29

"We have conducted a clinical and pharmacokinetic trial of the novel podophyllotoxin derivative NK611 administered orally for 21 consecutive days."

( Clinical and pharmacokinetic phase I trial of oral dimethylaminoetoposide (NK611) administered for 21 days every 35 days.
Hanauske, AR; Kaeser-Fröhlich, A; Rassmann, I; Rastetter, J; Schilling, T; Schrödel, H; Zucchetti, M, 1996)

0.29

" Pharmacokinetic analyses were performed in all patients."

( Phase I clinical and pharmacokinetic trial of the podophyllotoxin derivative NK611 administered as intravenous short infusion.
Berdel, WE; Burk, K; Fiebig, HH; Hanauske, AR; Hüttmann, A; Kaeser-Fröhlich, A; Manegold, C; Mross, M; Rassmann, I; Thödtmann, R, )

0.13

Excerpt	Reference	Relevance
" In one cancer patient who received both an oral and an intravenous dose of 10 mg of I the bioavailability was 82% and the clearance 20."	( High-performance liquid chromatographic assay for the determination of the novel podophyllotoxin derivative dimethylaminoetoposide (NK611) in human plasma. D'Incalci, M; De Fusco, M; Fröhlich, A; Reichert, S; Sessa, C; Zucchetti, M, 1994)	0.29
" Preclinical studies have shown that NK 611 is advantageous in terms of bioavailability and of the potency of its anticancer activity."	( Pharmacokinetics and pharmacodynamics of the new podophyllotoxin derivative NK 611. A study by the AIO groups PHASE-I and APOH. Burk, K; Hanauske, AR; Herbst, K; Hossfeld, DK; Hüttmann, A; Manegold, C; Mross, K; Schilling, T, 1996)	0.29
"NK611 is a novel water-soluble podophyllotoxin derivative that has comparable antitumour activity but higher potency and better bioavailability in animals as compared with etoposide."	( Clinical and pharmacokinetic study of oral NK611, a new podophyllotoxin derivative. Cavalli, F; D'Incalci, M; De Fusco, M; de Jong, J; Hanauske, A; Kaeser-Fröhlich, A; Pagani, O; Sessa, C; Zucchetti, M, 1996)	0.29

Excerpt

Reference

Relevance

" In one cancer patient who received both an oral and an intravenous dose of 10 mg of I the bioavailability was 82% and the clearance 20."

( High-performance liquid chromatographic assay for the determination of the novel podophyllotoxin derivative dimethylaminoetoposide (NK611) in human plasma.
D'Incalci, M; De Fusco, M; Fröhlich, A; Reichert, S; Sessa, C; Zucchetti, M, 1994)

0.29

" Preclinical studies have shown that NK 611 is advantageous in terms of bioavailability and of the potency of its anticancer activity."

0.29

"NK611 is a novel water-soluble podophyllotoxin derivative that has comparable antitumour activity but higher potency and better bioavailability in animals as compared with etoposide."

0.29

Excerpt	Relevance	Reference
" Since preliminary clinical information suggests that this drug is well tolerated at high doses, further development of this agent in Phase II trials with multiple dosing schedules is warranted."	( Activity of NK 611, a new epipodophyllotoxin derivative, against colony forming units from freshly explanted human tumours in vitro. Depenbrock, H; Hanauske, AR; Kaeser-Fröhlich, A; Lehmer, A; Rastetter, J; Rotter, M; Schneider, P; Wüster, KC, 1995)	0.29

Excerpt

Relevance

Reference

" Since preliminary clinical information suggests that this drug is well tolerated at high doses, further development of this agent in Phase II trials with multiple dosing schedules is warranted."

( Activity of NK 611, a new epipodophyllotoxin derivative, against colony forming units from freshly explanted human tumours in vitro.
Depenbrock, H; Hanauske, AR; Kaeser-Fröhlich, A; Lehmer, A; Rastetter, J; Rotter, M; Schneider, P; Wüster, KC, 1995)

0.29

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	10 (100.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe

Studies, This Drug (%)

All Drugs %

pre-1990

0 (0.00)

18.7374

1990's

10 (100.00)

18.2507

2000's

0 (0.00)

29.6817

2010's

0 (0.00)

24.3611

2020's

0 (0.00)

2.80

[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	5 (41.67%)	5.53%
Reviews	1 (8.33%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	6 (50.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type

This drug (%)

All Drugs (%)

Trials

5 (41.67%)

5.53%

Reviews

1 (8.33%)

6.00%

Case Studies

0 (0.00%)

4.05%

Observational

0 (0.00%)

0.25%

Other

6 (50.00%)

84.16%

[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
thiazoles [no description available]	1.98	1	0	1,3-thiazoles; mancude organic heteromonocyclic parent; monocyclic heteroarene
podophyllotoxin Podophyllum: A genus of poisonous American herbs, family BERBERIDACEAE. The roots yield PODOPHYLLOTOXIN and other pharmacologically important agents. The plant was formerly used as a cholagogue and cathartic. It is different from the European mandrake, MANDRAGORA.	7.35	10	4	furonaphthodioxole; lignan; organic heterotetracyclic compound	antimitotic; antineoplastic agent; keratolytic drug; microtubule-destabilising agent; plant metabolite; tubulin modulator
etoposide [no description available]	8.78	3	0	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
thiazolyl blue thiazolyl blue: RN & II refers to bromide. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide : The bromide salt of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium.	1.98	1	0	organic bromide salt	colorimetric reagent; dye
glycosides [no description available]	6.99	1	0
arginine Teniposide: A semisynthetic derivative of PODOPHYLLOTOXIN that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells from entering into the mitotic phase of the cell cycle, and lead to cell death. Teniposide acts primarily in the G2 and S phases of the cycle.. teniposide : A furonaphthodioxole that is a synthetic derivative of podophyllotoxin with anti-tumour activity; causes single- and double-stranded breaks in DNA and DNA-protein cross-links and prevents repair by topoisomerase II binding.	1.98	1	0

Condition	Relationship Strength	Studies	Trials
Benign Neoplasms [description not available]	5.2	4	3
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	5.2	4	3
Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)	1.98	1	0
Carcinoma, Oat Cell [description not available]	1.98	1	0
Adenocarcinoma, Basal Cell [description not available]	1.98	1	0
Carcinoma, Epidermoid [description not available]	1.98	1	0
Cancer of Lung [description not available]	3.77	2	1
Adenocarcinoma A malignant epithelial tumor with a glandular organization.	1.98	1	0
Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed)	1.98	1	0
Lung Neoplasms Tumors or cancer of the LUNG.	3.77	2	1
Carcinoma, Small Cell An anaplastic, highly malignant, and usually bronchogenic carcinoma composed of small ovoid cells with scanty neoplasm. It is characterized by a dominant, deeply basophilic nucleus, and absent or indistinct nucleoli. (From Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1286-7)	1.98	1	0
Disease Exacerbation [description not available]	3.37	1	1
Adrenal Cancer [description not available]	3.37	1	1
Bone Cancer [description not available]	3.37	1	1
Carcinoma, Non-Small Cell Lung [description not available]	3.37	1	1
Thrombopenia [description not available]	3.37	1	1
Bone Neoplasms Tumors or cancer located in bone tissue or specific BONES.	3.37	1	1
Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.	3.37	1	1
Neutropenia A decrease in the number of NEUTROPHILS found in the blood.	4.34	2	2
Thrombocytopenia A subnormal level of BLOOD PLATELETS.	3.37	1	1
Leukocytopenia [description not available]	3.37	1	1
Leukopenia A decrease in the number of LEUKOCYTES in a blood sample below the normal range (LEUKOCYTE COUNT less than 4000).	3.37	1	1
Leukemia L 1210 [description not available]	1.99	1	0
Leukemia P388 An experimental lymphocytic leukemia originally induced in DBA/2 mice by painting with methylcholanthrene.	1.99	1	0

nk 611

Description

Cross-References

Synonyms (9)

Research Excerpts

Pharmacokinetics

Bioavailability

Dosage Studied

Research

Studies (10)

Study Types

nk 611

Description

Cross-References

Synonyms (9)

Research Excerpts

Pharmacokinetics

Bioavailability

Dosage Studied

Research

Studies (10)

Study Types

Related Drugs (6)

Related Conditions (24)